Drug intelligence / Profile preview

KYG0395

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

KYG0395 is an investigational drug currently being studied for the treatment of primary dysmenorrhea, which is characterized by cramping pain in the lower abdomen and/or pelvis just before or during menstruation. The drug is being evaluated for its efficacy, safety, and dose-response in adult women aged 18 to 35 with primary dysmenorrhea. Clinical trials are comparing KYG0395 to placebo to determine its effectiveness in reducing menstrual pain. The specific mechanism of action and molecular target of KYG0395 have not been disclosed in publicly available sources[1][2][4].

Brand names: Guizhi Fuling Capsule
Other names: Guizhi Fuling WanGui Zhi Fu Ling WanGZFLC

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on KYG0395.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KYG0395.

Explore the full profile